0115 Arcus Pancreatic
BioCentury & Getty Images

Product Development

Readout for Arcus’ pancreatic cancer program could spur Gilead to exercise option

Jan 15, 2021 | 11:37 PM GMT

Early data showing clinical efficacy of a combination from Arcus in pancreatic cancer increases the likelihood that Gilead will exercise its option on the biotech’s potentially first-in-class molecule targeting CD73.


Read the full 553 word article

How to gain access

Continue reading with a
two-week free trial.